ADPT Adaptive Biotechnologies Corporation - Fundamental Analysis
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Valuation is based on growth expectations, not fundamentals; stock trades at a premium due to high growth potential but lacks earnings support.
- High revenue growth (51% YoY)
- Strong earnings surprise history (74.22% avg)
- Gross margin of 40.38%
- No Graham Number or intrinsic value due to negative earnings
- Price/Sales of 8.44 is high for a loss-making company
- Forward P/E of -56.30 reflects deep unprofitability
Future outlook is optimistic on growth but highly speculative due to persistent losses and lack of cash conversion.
- 51% YoY revenue growth
- Recent earnings beats and positive surprises
- Strong analyst target price ($20.86)
- Negative earnings and ROE
- Forward P/E of -56.30 indicates no near-term profitability
- No free cash flow data available
Past performance shows improvement in earnings surprise but persistent unprofitability and declining long-term returns.
- Consistent earnings beat rate (3/4 in last 4 quarters)
- Improving EPS trend (60.9% YoY EPS growth)
- Positive Q/Q EPS growth of -250.0% (likely due to base effect)
- 5-year price decline of -73.2%
- Negative ROE and ROA for multiple years
- Historical losses with no sustained profitability
Despite strong liquidity, the company's operational and financial health is weak, with minimal profitability and high risk of deterioration.
- Current ratio of 3.34 and quick ratio of 3.08 indicate strong liquidity
- Debt/Equity of 0.93 is moderate
- Piotroski F-Score of 1/9 signals severe financial distress
- No Altman Z-Score available; risk of distress is elevated
- Negative ROE (-27.82%) and ROA (-6.79%) indicate poor capital efficiency
No dividend policy; all capital is reinvested into growth, which is typical for early-stage biotech but increases risk for income investors.
- No dividend yield or payout ratio
- Dividend strength of 0/100
- Company is not dividend-paying
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ADPT and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ADPT
Adaptive Biotechnologies Corporation
Primary
|
-73.2% | +72.7% | +82.5% | +16.9% | -13.5% | -5.2% |
|
AAPG
Ascentage Pharma Group Internat
Peer
|
+43.4% | +43.4% | +26.7% | -48.0% | -5.5% | +4.7% |
|
ATEC
Alphatec Holdings, Inc.
Peer
|
+4.7% | +20.4% | +33.9% | +44.4% | -24.8% | -11.9% |
|
BHC
Bausch Health Companies Inc.
Peer
|
-78.1% | -29.4% | -24.3% | -12.7% | -17.7% | -15.3% |
|
ADUS
Addus HomeCare Corporation
Peer
|
-0.0% | +9.6% | +3.0% | -2.5% | +5.2% | +1.5% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ADPT
Adaptive Biotechnologies...
|
BEARISH | $2.34B | - | -27.8% | -21.5% | $15.2 | |
|
AAPG
Ascentage Pharma Group Internat
|
BEARISH | $2.33B | - | -159.6% | -296.8% | $24.93 | |
|
ATEC
Alphatec Holdings, Inc.
|
BEARISH | $2.32B | - | -540.4% | -21.3% | $15.62 | |
|
BHC
Bausch Health Companies Inc.
|
BEARISH | $2.19B | 6.79 | 563.2% | 3.6% | $5.91 | |
|
ADUS
Addus HomeCare Corporation
|
BULLISH | $2.13B | 24.83 | 8.6% | 6.4% | $115.48 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-04 | PISKEL KYLE | Chief Financial Officer | Sale | 2,145 | $39,597 |
| 2026-02-04 | PISKEL KYLE | Chief Financial Officer | Option Exercise | 2,145 | $26,040 |
| 2026-02-03 | ROBINS HARLAN S. | Officer | Sale | 42,788 | $799,105 |
| 2026-02-02 | ROBINS CHAD M | Chief Executive Officer | Sale | 124,998 | $2,304,963 |
| 2026-01-12 | LO FRANCIS | Officer | Sale | 79,590 | $1,411,131 |
| 2026-01-12 | LO FRANCIS | Officer | Option Exercise | 79,590 | $614,022 |
| 2026-01-12 | PISKEL KYLE | Chief Financial Officer | Sale | 4,290 | $77,220 |
| 2026-01-12 | PISKEL KYLE | Chief Financial Officer | Option Exercise | 4,290 | $52,081 |
| 2026-01-06 | ROBINS HARLAN S. | Officer | Sale | 10,000 | $164,400 |
| 2026-01-05 | ROBINS CHAD M | Chief Executive Officer | Sale | 124,998 | $1,948,719 |
| 2026-01-02 | LO FRANCIS | Officer | Sale | 3,125 | $50,250 |
| 2026-01-02 | LO FRANCIS | Officer | Option Exercise | 3,125 | $12,469 |
| 2025-12-22 | LO FRANCIS | Officer | Sale | 4,394 | $76,895 |
| 2025-12-22 | LO FRANCIS | Officer | Option Exercise | 4,394 | $31,530 |
| 2025-12-22 | LO FRANCIS | Officer | Sale | 4,394 | $76,895 |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning ADPT from our newsroom.